Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRMD | CORMEDIX INC | $876.97M | $12.93 | $16.50 | 27.61% | Buy | 6 | 62.20% | 115.44% | 172.68% | 132.63% | |||
| TGTX | TG THERAPEUTICS INC | $4.46B | $28.08 | $55.00 | 95.87% | Buy | 1 | 29.44% | 78.04% | 189.41% | 74.52% | |||
| CORT | CORCEPT THERAPEUTICS INC | $7.56B | $71.75 | $138.25 | 92.70% | Strong Buy | 4 | 30.18% | 51.02% | 128.03% | 101.53% | |||
| GYRE | GYRE THERAPEUTICS INC | $783.99M | $8.14 | N/A | N/A | N/A | N/A | 51.23% | 252.59% | 303.51% | 182.98% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $2.47B | $33.38 | $42.50 | 27.32% | Strong Buy | 4 | 21.07% | 229.06% | 42.44% | 31.78% | |||
| KRYS | KRYSTAL BIOTECH INC | $4.35B | $150.27 | $203.56 | 35.46% | Strong Buy | 9 | 33.35% | 32.89% | 36.39% | 33.27% | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.87B | $67.27 | $70.60 | 4.95% | Buy | 5 | 12.73% | 20.02% | 308.98% | 50.06% | |||
| ARGX | ARGENX SE | $39.91B | $653.83 | $780.30 | 19.34% | Strong Buy | 10 | 1,380.94% | 7.58% | 35.88% | 30.48% | |||
| RPRX | ROYALTY PHARMA PLC | $21.20B | $36.35 | $48.00 | 32.05% | Strong Buy | 2 | 19.54% | 48.51% | 33.32% | 17.28% | |||
| INVA | INNOVIVA INC | $1.32B | $20.92 | $40.25 | 92.40% | Strong Buy | 4 | 12.10% | 60.24% | 26.89% | 14.41% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.62B | $12.27 | $13.00 | 5.95% | Buy | 2 | 13.31% | 28.29% | 49.07% | 32.74% | |||
| VCEL | VERICEL CORP | $1.83B | $36.28 | $59.00 | 62.62% | Strong Buy | 4 | 19.25% | 86.26% | 24.83% | 17.49% | |||
| EXEL | EXELIXIS INC | $10.31B | $38.31 | $45.73 | 19.38% | Buy | 15 | 10.28% | 21.42% | 69.43% | 52.72% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.12B | $36.87 | $54.14 | 46.85% | Strong Buy | 7 | 13.74% | 15.31% | 44.58% | 31.10% | |||
| INCY | INCYTE CORP | $16.97B | $86.92 | $79.42 | -8.63% | Buy | 12 | 8.42% | 21.72% | 41.69% | 29.87% | |||
| ADMA | ADMA BIOLOGICS INC | $4.05B | $16.99 | $28.50 | 67.75% | Strong Buy | 2 | 18.62% | 13.60% | 100.65% | 71.80% | |||
| MNKD | MANNKIND CORP | $1.14B | $3.73 | $8.00 | 114.48% | Buy | 2 | 13.68% | 22.05% | -236.91% | 31.67% | |||
| ATRA | ATARA BIOTHERAPEUTICS INC | $86.31M | $12.29 | $17.00 | 38.32% | Strong Buy | 1 | -39.64% | 56.54% | N/A | N/A | |||
| MDXG | MIMEDX GROUP INC | $1.05B | $7.11 | $12.00 | 68.78% | Strong Buy | 1 | 10.22% | 42.65% | N/A | N/A | |||
| TECH | BIO-TECHNE CORP | $8.40B | $53.60 | $67.80 | 26.49% | Buy | 10 | 5.16% | 55.33% | 15.56% | 11.87% | |||
| VCYT | VERACYTE INC | $2.37B | $30.22 | $42.00 | 38.98% | Strong Buy | 5 | 8.66% | 49.47% | 7.44% | 6.76% | |||
| NVO | NOVO NORDISK A S | $234.01B | $52.41 | $64.00 | 22.11% | Hold | 1 | 5.56% | 5.59% | 97.75% | 34.07% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.05B | $57.54 | $98.17 | 70.61% | Strong Buy | 12 | 7.32% | 17.89% | N/A | N/A | |||
| NAGE | NIAGEN BIOSCIENCE INC | $799.12M | $10.02 | $14.78 | 47.46% | Strong Buy | 4 | 15.50% | 0.11% | 38.51% | 27.01% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.48B | $20.23 | $33.33 | 64.77% | Strong Buy | 3 | 7.90% | 14.12% | 38.03% | 33.50% | |||
| GMAB | GENMAB A | $14.95B | $23.31 | $41.00 | 75.89% | Strong Buy | 2 | 14.55% | 8.78% | 4.39% | 3.60% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $100.71B | $392.79 | $489.19 | 24.54% | Buy | 16 | 7.20% | 10.17% | N/A | N/A |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.